Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.
Casacó A, López G, García I, Rodríguez JA, Fernández R, Figueredo J, Torres L, Perera A, Batista J, Leyva R, Peña Y, Amador Z, González A, Estupiñan B, Coca M, Hernández A, Puig M, Iglesias M, Hernández A, Ramos M, Rodríquez L, Suarez N.
Casacó A, et al. Among authors: gonzalez a.
Cancer Biol Ther. 2008 Mar;7(3):333-9. doi: 10.4161/cbt.7.3.5414. Epub 2007 Dec 13.
Cancer Biol Ther. 2008.
PMID: 18094616
Free article.
Clinical Trial.